Reuters logo
BRIEF-Sanofi announces that Soliqua (TM) 100/33 now available in United States
January 4, 2017 / 6:10 AM / 9 months ago

BRIEF-Sanofi announces that Soliqua (TM) 100/33 now available in United States

Jan 4 (Reuters) - Sanofi :

* Sanofi announced today that Soliqua(TM) 100/33 (insulin glargine 100 Units/mL & lixisenatide(*) 33 mcg/mL injection) is now available by prescription in U.S. pharmacies.

* Soliqua 100/33 is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide.

* “We are encouraged by the potential of Soliqua 100/33, which has demonstrated superior HbA1c lowering versus Lantus,” said Peter Guenter, Executive Vice President, Head, Global Diabetes & Cardiovascular Business Unit, Sanofi.

Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below